Frédérique Rousseau

1.3k total citations
60 papers, 744 citations indexed

About

Frédérique Rousseau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Geriatrics and Gerontology. According to data from OpenAlex, Frédérique Rousseau has authored 60 papers receiving a total of 744 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Geriatrics and Gerontology. Recurrent topics in Frédérique Rousseau's work include Frailty in Older Adults (15 papers), Nutrition and Health in Aging (10 papers) and Cancer Treatment and Pharmacology (9 papers). Frédérique Rousseau is often cited by papers focused on Frailty in Older Adults (15 papers), Nutrition and Health in Aging (10 papers) and Cancer Treatment and Pharmacology (9 papers). Frédérique Rousseau collaborates with scholars based in France, Italy and Belgium. Frédérique Rousseau's co-authors include Jean Marc Extra, René Bruno, N Le Bail, M. Marty, M. Clavel, Patrice Viens, F. Rétornaz, Christel Protière, Jean Paul Moatti and Dominique Rey and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Frédérique Rousseau

53 papers receiving 728 citations

Peers

Countries citing papers authored by Frédérique Rousseau

Since Specialization

Citations

This map shows the geographic impact of Frédérique Rousseau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédérique Rousseau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédérique Rousseau more than expected).

Fields of papers citing papers by Frédérique Rousseau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédérique Rousseau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédérique Rousseau. The network helps show where Frédérique Rousseau may publish in the future.

Co-authorship network of co-authors of Frédérique Rousseau

This figure shows the co-authorship network connecting the top 25 collaborators of Frédérique Rousseau. A scholar is included among the top collaborators of Frédérique Rousseau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédérique Rousseau. Frédérique Rousseau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know? 2024 ·Cancers ·(unknown), Renaud Sabatier, Frédérique Rousseau, Alexandre de Nonneville, Anthony Gonçalvès, (unknown), (unknown), F. Viret, (unknown), Maria Kfoury, (unknown), (unknown), (unknown)	2
2	How to compensate for frailty? The real life impact of geriatric co-management on morbi-mortality after colorectal cancer surgery in patients aged 70 years or older 2024 ·Aging Clinical and Experimental Research ·(unknown), Hélène Meillat, (unknown), Bernard Lelong, Frédérique Rousseau, (unknown), (unknown)	3
3	Quality of life in older French long-term lung cancer survivors: VICAN5 national survey 2023 ·Lung Cancer ·Anne‐Laure Couderc, Anne‐Déborah Bouhnik, Dominique Rey, Marc‐Karim Bendiane, Laurent Greillier, (unknown), (unknown), (unknown), Frédérique Rousseau, P. Villani, Julien Mancini	2
4	Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study 2022 ·The Lancet Healthy Longevity ·Claire Falandry, Fanny Pommeret, Laurence Gladieff, Fabien Tinquaut, Domenica Lorusso, Marie‐Ange Mouret‐Reynier, Véronique D’Hondt, (unknown), Anne Floquet, Sophie Abadie‐Lacourtoisie, Pierre-Emmanuel Brachet, Laëtitia Stefani, Frédérique Rousseau, Jean‐Sébastien Frenel, Francesco Del Piano, Marja Komulainen, (unknown), Olivier Trédan, Éric Pujade-Lauraine, Gilles Freyer	7
5	Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial 2022 ·European Journal of Cancer ·Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, (unknown), (unknown), Saverio Cinieri, Eva María Guerra Alia, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, (unknown), Ulrich Canzler, Alain Gratet, Frederik Marmé, Laure Favier, Éric Pujade-Lauraine, Isabelle Ray‐Coquard	13
6	Lived experience and perceived advantages of therapeutic De-escalation: A qualitative study of older patients with breast cancer 2022 ·Journal of Geriatric Oncology ·(unknown), Marc‐Karim Bendiane, (unknown), Frédérique Rousseau, Dominique Rey, (unknown), (unknown), Marie‐Anne Durand, Agnès Tallet, Julien Mancini	4
7	Patients très âgés dans les RCP en région PACA : observation sur une année 2021 ·Bulletin du Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Frédérique Rousseau	0
8	739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial 2021 ·Annals of Oncology ·Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, (unknown), (unknown), Saverio Cinieri, (unknown), Gerhard Bogner, Hiroyuki Yoshida, I. Vergote, N. Colombo, (unknown), R. Largillier, Ulrich Canzler, Alain Gratet, Frederik Marmé, Eric Pujade‐Lauraine, Laure Favier, I. L. Ray-Coquard	1
9	Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020 2020 ·Journal of Geriatric Oncology ·Marine Gilabert, Pauline Ries, Brice Chanez, (unknown), Éric François, Astrid Lièvre, Frédérique Rousseau	1
10	Use's assessment of geriatric variables in the older patient with cancer's multidisciplinary team meeting 2019 ·Journal of Geriatric Oncology ·(unknown), (unknown), Matthieu Sarabi, (unknown), (unknown), G. Albrand, C. Terret, Frédérique Rousseau	3
11	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer 2018 ·Journal of Geriatric Oncology ·Renaud Sabatier, (unknown), (unknown), A.‐P. Jonville‐Béra, Anne Madroszyk, (unknown), (unknown), Ségolène Duran, (unknown), Franck Rouby, Joëlle Micallef, Frédérique Rousseau	17
12	A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study 2017 ·Supportive Care in Cancer ·Brice Chanez, François Bertucci, Marine Gilabert, Anne Madroszyk, Frédérique Rousseau, (unknown), Patrice Viens, Jean‐Luc Raoul	3
13	Haploidentical Hematopoietic Stem Cell Allogeneic Transplantation with High Dose Post Transplantation Cyclophosphamide for Patients over 60 Years of Age 2017 ·Blood ·Samia Harbi, Raynier Devillier, Stéfania Bramanti, Thomas Pagliardini, Faézeh Legrand, (unknown), Valério Maisano, (unknown), Angéla Granata, Frédérique Rousseau, Sabine Fürst, Catherine Faucher, Christian Chabannon, Pierre Jean Weiller, Luca Castagna, Didier Blaise	1
14	High-grade glioma in elderly patients: can the oncogeriatrician help? 2013 ·Clinical Interventions in Aging ·Frédérique Rousseau, Émeline Tabouret, (unknown), Olivier Chinot, E. Crétel	5
15	Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer 2013 ·PLoS ONE ·Laëtitia Huiart, Anne‐Déborah Bouhnik, Dominique Rey, Frédérique Rousseau, F. Rétornaz, (unknown), Marc‐Karim Bendiane, Patrice Viens, Roch Giorgi	24
16	Are there candidates for high-dose chemotherapy in ovarian carcinoma? 2012 ·Journal of Experimental & Clinical Cancer Research ·Renaud Sabatier, Anthony Gonçalvès, François Bertucci, (unknown), Frédérique Rousseau, Éric Lambaudie, Christian Chabannon, Patrice Viens, Jean-Marc Extra	7
17	Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial 2010 ·Critical Reviews in Oncology/Hematology ·Étienne Brain, C. Mertens, Véronique Girre, Frédérique Rousseau, Emmanuel Blot, (unknown), Lionel Uwer, Emmanuelle Bourbouloux, (unknown), Loı̈c Mourey, Sylvie Kirscher, Brigitte Laguerre, Emmanuelle Fourme, (unknown), Jean Genève, Marc Debled	38
18	Prescribers’ attitudes toward elderly breast cancer patients. Discrimination or empathy? 2009 ·Critical Reviews in Oncology/Hematology ·Christel Protière, Patrice Viens, Frédérique Rousseau, Jean Paul Moatti	39
19	Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients 2007 ·Oncology ·Jean‐Emmanuel Kurtz, Frédérique Rousseau, Nicolás Meyer, T. Delozier, D. Serin, (unknown), (unknown), P. Dufour	11
20	Poulets de chair : effets respectifs de l'âge et du poids d'abattage sur les caractéristiques lipidiques et sensorielles des muscles 1996 ·HAL (Le Centre pour la Communication Scientifique Directe) ·(unknown), Frédérique Rousseau, (unknown), (unknown), G. Gandemer	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact